Targeting metastasis in paediatric bone sarcomasKarolinska Inst, Sweden.
IRCCS Ist Ortoped Rizzoli, Italy.
IRCCS Ist Ortoped Rizzoli, Italy.
Tech Univ Munich, Germany.
Univ Sheffield, England.
Gustave Roussy Inst, France.
Gustave Roussy Inst, France; Gustave Roussy Canc Campus, France.
Gustave Roussy Inst, France.
Anticanc Fund, Belgium; George Pantziarka TP53 Trust, England.
Royal Natl Orthopaed Hosp, England.
Royal Natl Orthopaed Hosp, England.
Univ Sheffield, England.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences.
Gustave Roussy Inst, France.
Ippokratio Gen Hosp Thessaloniki, Greece.
St Anna Childrens Canc Res Inst, Austria; Med Univ Vienna, Austria.
Univ Zurich, Switzerland.
Univ Sheffield, England; Nantes Univ, France; Inst Cancerol Ouest, France.
Hopp Childrens Canc Ctr KITZ, Germany; German Canc Consortium DKTK, Germany; Partnership DKFZ & Univ Hosp Heidelberg, Germany.
Univ Paris Saclay, France.
Liverpool John Moores Univ, England.
Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
Hopp Childrens Canc Ctr KITZ, Germany; German Canc Consortium DKTK, Germany; Partnership DKFZ & Univ Hosp Heidelberg, Germany; Heidelberg Univ Hosp, Germany.
IRCCS Ist Ortoped Rizzoli, Italy.
Tech Univ Munich, Germany; Klinikum Kassel, Germany.
Univ East Anglia, England.
Show others and affiliations
2025 (English)In: Molecular Cancer, E-ISSN 1476-4598, Vol. 24, no 1, article id 153
Article, review/survey (Refereed) Published
Abstract [en]
Paediatric bone sarcomas (e.g. Ewing sarcoma, osteosarcoma) comprise significant biological and clinical heterogeneity. This extreme heterogeneity affects response to systemic therapy, facilitates inherent and acquired drug resistance and possibly underpins the origins of metastatic disease, a key component implicit in cancer related death. Across all cancers, metastatic models have offered competing accounts on when dissemination occurs, either early or late during tumorigenesis, whether metastases at different foci arise independently and directly from the primary tumour or give rise to each other, i.e. metastases-to-metastases dissemination, and whether cell exchange occurs between synchronously growing lesions. Although it is probable that all the above mechanisms can lead to metastatic disease, clinical observations indicate that distinct modes of metastasis might predominate in different cancers. Around 70% of patients with bone sarcoma experience metastasis during their disease course but the fundamental molecular and cell mechanisms underlying spread are equivocal. Newer therapies such as tyrosine kinase inhibitors have shown promise in reducing metastatic relapse in trials, nonetheless, not all patients respond and 5-year overall survival remains at similar to 50%. Better understanding of potential bone sarcoma biological subgroups, the role of the tumour immune microenvironment, factors that promote metastasis and clinical biomarkers of prognosis and drug response are required to make progress. In this review, we provide a comprehensive overview of the approaches to manage paediatric patients with metastatic Ewing sarcoma and osteosarcoma. We describe the molecular basis of the tumour immune microenvironment, cell plasticity, circulating tumour cells and the development of the pre-metastatic niche, all required for successful distant colonisation. Finally, we discuss ongoing and upcoming patient clinical trials, biomarkers and gene regulatory networks amenable to the development of anti-metastasis medicines.
Place, publisher, year, edition, pages
BMC , 2025. Vol. 24, no 1, article id 153
Keywords [en]
Ewing sarcoma; Osteosarcoma; Bone; Sarcoma; Metastasis
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-214455DOI: 10.1186/s12943-025-02365-zISI: 001499302500001PubMedID: 40442778Scopus ID: 2-s2.0-105006883971OAI: oai:DiVA.org:liu-214455DiVA, id: diva2:1967030
Note
Funding Agencies|City of London Corporation through The Sir William Coxen Trust Fund; Children with Cancer UK; Children's Cancer and Leukaemia Group, Bone Cancer Research Trust; Richard Jenner Memorial Trust; Sophie's Sparkle Fund; Peter Stebbings Memorial Charity; Swedish Cancer Society; Swedish Childhood Cancer Fund; Swedish Research Council; AIRC Foundation for Cancer Research, Italian Ministry of Health; Swedish Foundation for Strategic Research, Austrian National Bank's Jubilumsfonds, Vienna Science and Technology Fund (WWTF); German Cancer Aid; German Child Cancer Foundation; Society for Pediatric Oncology and Hematology; Barbara and Wilfried Mohr Foundation; Cancer Grand Challenge program (PROTECT); European Union (ERC) [101122595]
2025-06-112025-06-112025-09-22